Your browser is no longer supported. Please, upgrade your browser.
ANCN Anchiano Therapeutics Ltd. monthly Stock Chart
Anchiano Therapeutics Ltd.
Index- P/E- EPS (ttm)-2.03 Insider Own3.89% Shs Outstand7.42M Perf Week-0.82%
Market Cap11.33M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float3.08M Perf Month23.17%
Income- PEG- EPS next Q- Inst Own4.42% Short Float0.40% Perf Quarter57.49%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.03 Perf Half Y32.69%
Book/sh0.72 P/B2.12 EPS next Y- ROA- Target Price- Perf Year-5.14%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.51 - 2.72 Perf YTD9.09%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.85% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low197.36% ATR0.16
Employees16 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)58.73 Volatility6.60% 15.98%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close1.51
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume450.12K Price1.53
Recom3.00 SMA205.98% SMA5019.81% SMA20041.00% Volume19,180 Change1.15%
Nov-18-19Downgrade Oppenheimer Outperform → Perform
Nov-18-19Downgrade Ladenburg Thalmann Buy → Neutral
May-29-19Initiated Robert W. Baird Outperform $12
Oct-08-20 12:00PM  
May-26-20 08:00AM  
May-11-20 04:01PM  
May-05-20 06:13PM  
Apr-17-20 04:01PM  
Mar-18-20 08:00AM  
Jan-17-20 04:05PM  
Nov-15-19 08:30AM  
Oct-24-19 04:05PM  
Sep-23-19 05:03PM  
Sep-20-19 08:30AM  
Sep-03-19 08:00AM  
Aug-05-19 05:15PM  
Jun-18-19 08:30AM  
May-29-19 08:30AM  
May-22-19 09:00AM  
Mar-14-19 05:42PM  
Mar-12-19 04:15PM  
Feb-14-19 04:40PM  
Feb-12-19 03:21PM  
Feb-10-19 06:51PM  
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.